EP4648776A1 — Compositions and methods for the treatment and/or prevention of type 1 diabetes
Assigned to Pfizer Inc · Expires 2025-11-19 · 0y expired
What this patent protects
The present disclosure relates to the field of Type 1 diabetes. More specifically, the present disclosure provides pharmaceutical compositions and methods for treating and/or preventing Type 1 diabetes. In certain embodiments, pharmaceutical compositions and methods comprise admi…
USPTO Abstract
The present disclosure relates to the field of Type 1 diabetes. More specifically, the present disclosure provides pharmaceutical compositions and methods for treating and/or preventing Type 1 diabetes. In certain embodiments, pharmaceutical compositions and methods comprise administering to a patient or subject a therapeutically effective amount of a JAK1 inhibitor, for 5 example, abrocitinib. In certain embodiments, pharmaceutical compositions and methods comprise administering to a patient or subject a therapeutically effective amount of a JAK3/TEC inhibitor, for example ritlecitinib.
Drugs covered by this patent
- Litfulo (Ritlecitinib Tosylate) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.